There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique challenges. In the face of multiple options to appropriately treat and manage CAT, thrombosis is a complication that HCPs are not recognizing early enough; plus, there is a lack of awareness of new CAT management clinical data. While the morbidity and mortality of VTE in patients with cancer remain high, unfortunately, the management of it does not take the same priority. While recommendations suggest an individualized approach to managing these patients, adoption into clinical practice lags. Published guidelines and clinical trial data do not necessarily align with real-world practice and prescribing behaviors. As a result, many existing protocols for CAT management require updates, as new guidance is warranted. This program focuses on managing cancer-associated venous thromboembolic disease, with a special emphasis on translating real-world data and evidence-based medicine, including recent clinical guidelines, into clinical practice.